Moreover, unlike tumor-associated antigens (TAA) that are shared between tumor cells and normal tissue (e.g., Melan A/MART-1) neoantigens have a selective potential to elicit tumor exclusive T cell responses which makes them key elements for inclusion in cancer vaccines and as the basis for adoptive T cell transfer approaches (10–14). Here, MLANA is linked to cancer.